CONTOURA® Vision Pearls Collection (17 videos)

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

CONTOURA® Vision vs Conventional Wavefront Treatment

Channels: Cataract Surgery, Refractive

A panel of physicians explains why topography-guided customized ablation treatment (T-CAT) is a better alternative to conventional, wavefront-optimized and wavefront-customized treatment methods. Ronald Krueger, MD, explains how CONTOURA® Vision allows surgeons to treat patients at the level of the cornea without inducing aberrations. Karl G. Stonecipher, MD, says that, with CONTOURA® Vision, surgeons can now customize treatment options to provide the best outcomes for patients.

Topoguided EL custom ablation treatment,TCAT,t-cat • Wavelight Ex500 Excimer Laser

More Videos from CONTOURA® Vision Pearls


WaveLight® Excimer Laser Systems Important Product Information

This information pertains to all WaveLight® Excimer Laser Systems, including the WaveLight® ALLEGRETTO WAVE®, the ALLEGRETTO WAVE® Eye-Q , and the WaveLight® EX500.

Caution: Federal (U.S.) law restricts the WaveLight® Excimer Laser Systems to sale by or on the order of a physician. Only practitioners who are experienced in the medical mangement and surgical treatment of the cornea, who have been trained in laser refractive surgery (including laser calibration and operation) should use a WaveLight® Excimer Laser System.

Indications: FDA has approved the WaveLight® Excimer Laser systems for use in laser-assisted in situ keratomileusis (LASIK) treatments for:

  • the reduction or elimination of myopia of up to - 12.00 D and up to 6.00 D of astigmatism at the spectacle plane;
  • the reduction or elimination of hyperopia up to + 6.00 D with and without astigmatic refractive errors up to 5.00 D at the spectacle plane, with a maximum manifest refraction spherical equivalent of + 6.00 D;
  • the reduction or elimination of naturally occurring mixed astigmatism of up to 6.00 D at the spectacle plane; and
  • the wavefront-guided reduction or elimination of myopia of up to -7.00 D and up to 3.00 D of astigmatism at the spectacle plane.

©2018 Novartis 05/18 US-WVL-17-E-1518(1)